LTM (a leading Indian medtech contract manufacturing and design services provider) has signed a $100 million multi-year strategic agreement with a major European medical device company. The deal covers end-to-end design, development, regulatory support, and large-scale manufacturing of next-generation Class IIb and Class III devices, significantly boosting LTM’s global footprint and reinforcing India’s position as a preferred outsourcing destination for high-value medtech.
Glimpse:
The multi-year contract, valued at $100 million over its initial term, involves LTM taking responsibility for product design transfer, validation, clinical evaluation support, and commercial-scale production of advanced interventional and implantable devices. The partnership includes dedicated cleanroom capacity expansion at LTM’s facilities in India and joint investment in process automation and quality systems to meet stringent EU MDR requirements. The agreement is expected to generate recurring revenue, create hundreds of skilled jobs, and position LTM as a strategic manufacturing partner for European OEMs seeking cost-competitive, high-quality supply chains.
LTM, one of India’s fastest-growing contract development and manufacturing organizations (CDMO) in the medical device sector, has announced the signing of a transformative $100 million multi-year agreement with an undisclosed leading European medtech company. The deal, finalized after months of technical and commercial negotiations, marks one of the largest single outsourcing contracts awarded to an Indian medtech firm in recent years.
Under the agreement, LTM will serve as the strategic manufacturing and development partner for a portfolio of high-complexity Class IIb and Class III medical devices used in interventional cardiology, neurovascular procedures, structural heart interventions, and minimally invasive surgery. The scope covers full product lifecycle support from design transfer and process validation to regulatory documentation (EU MDR technical files), clinical evaluation, and commercial-scale production.
The European partner selected LTM after a rigorous global vendor evaluation process citing the company’s proven track record in complex device manufacturing, strong quality systems (ISO 13485 certified with MDSAP and EU MDR readiness), robust supply chain localization, and ability to deliver at scale with competitive cost structures. LTM will dedicate new cleanroom capacity, automated assembly lines, and specialized testing infrastructure at its existing facilities in India, with phased investments already underway.
The contract is structured as a multi-year take-or-pay agreement with built-in volume ramp-up milestones and pricing incentives tied to performance and quality metrics. It is expected to contribute meaningfully to LTM’s revenue growth starting from FY27 and strengthen its position as a preferred partner for global OEMs seeking to diversify supply chains away from traditional manufacturing hubs while maintaining European regulatory compliance.
LTM leadership highlighted that the deal validates India’s maturing medtech ecosystem and the country’s ability to handle end-to-end manufacturing of high-risk, high-precision devices. The company plans to use the partnership as a reference to attract additional global contracts in structural heart, neurovascular, and orthopaedic segments.
Industry analysts view the transaction as a strong signal of confidence in Indian medtech capabilities and expect it to accelerate further outsourcing from Europe and the US to cost-competitive, quality-focused partners like LTM. The deal also aligns with India’s National Medical Devices Policy 2023 and PLI scheme objectives of increasing domestic value addition and exports.
“This $100 million partnership is a testament to India’s growing stature in global medtech manufacturing. We are proud to deliver European-quality devices at Indian speed and scale.”
By
HB Team
Related News
